

Pharmaceutical Services, 2 Franklin Street, Belfast BT2 8DQ
Telephone No. 028 95 36 0333

Trurapi® (insulin aspart) 100units/ml solution for injection 3ml pre-filled Solostar pens
Tier 2 – medium impact*
Date of issue: 18/05/2026

[Medicines Supply Tool – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice](#)

Summary

- Trurapi® (insulin aspart) 100units/ml solution for injection 3ml pre-filled Solostar pens are in limited supply until late May 2026, followed by an out of stock period until mid-June 2026.
- Trurapi® 100units/ml solution for injection 3ml cartridges remain available and can support increased demand. These are compatible with the AllStar® PRO and JuniorSTAR® pens, which can also support increased demand.
- NovoRapid® FlexPen® (insulin aspart) 100units/ml solution for injection 3ml pre-filled pens remain available and can support increased demand.
- Fiasp® (insulin aspart) products remain available **but are not interchangeable** with Trurapi® due to differences in bioavailability.

Actions Required

Clinicians should:

- not initiate any new patients on Trurapi® (insulin aspart) 100units/ml solution for injection 3ml pre-filled Solostar pens until the shortage has resolved;
- review existing patients currently prescribed Trurapi® Solostar pens and where they have insufficient supplies to last until the re-supply date, consider prescribing the following alternatives until the shortage resolves:
 - Trurapi® (insulin aspart) 100units/ml solution for injection 3ml cartridges with AllStar® PRO or JuniorSTAR® pens, (see Supporting information) and where this is not appropriate;
 - NovoRapid® Flexpen® (insulin aspart) 100units/ml pre-filled pen.

When prescribing alternatives:

- consider local prescribing policies/formularies, manual dexterity, vision, and whether additional support is required for administration;
- ensure that all patients are informed of the reason for the switch, and that they are receiving the same type of insulin but initially they may need to check their blood glucose levels more closely to ensure control;
- provide patients with training on the use of their new device, including signposting to training videos (see Links); and
- provide patients with the appropriate delivery device, needles and a sharps bin.

If the above options are not considered suitable; seek advice from specialist diabetes teams on management options.

Supporting Information

Clinical Information

Trurapi® is a biosimilar of **NovoRapid®**, licensed for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Trurapi® cartridges are intended for use in the following designated reusable pens which can be prescribed on an FP10:

- AllStar® PRO delivers 1 to 80 units in 1-unit dose increments
- JuniorSTAR® delivers 1 to 30 units in 0.5-unit dose increments

Fiasp® is another insulin aspart formulation, **but it is not interchangeable** with Trurapi® and NovoRapid® due to differences in bioavailability.

Links to further information

[BNF- insulin aspart](#)

[SmPC – Trurapi® Solostar® 100units/ml solution for injection in pre-filled pen](#)

[SmPC – Trurapi® 100units/ml solution for injection 3ml cartridge](#)

[SmPC – NovoRapid® FlexPen® 100units/ml solution for injection 3ml pre-filled pen](#)

[Novo Nordisk® injection devices and needles](#)

[Novo Nordisk® FlexPen® webpage](#)

[Patient booklet for AllStar® PRO pen for Trurapi®](#)

[Patient booklet for JuniorSTAR® pen for Trurapi®](#)

[SPS: Safety considerations when switching insulin products](#)